Trial Profile
Multicenter Randomized Phase III Clinical Trial to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) Vs. [versus] 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Therapeutic Use
- 14 Feb 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2018 Status changed from completed to active, no longer recruiting.
- 12 Mar 2018 Results (n=571) of sub study published in the European Journal of Cancer.